AstraZeneca Plc (AZN)'s profit rose more than analysts anticipated last quarter, buoyed by demand for its blockbuster cancer and diabetes drugs. CEO Pascal Soriot joined Bloomberg's The Opening Trade to discuss their latest earnings and outlook.

Bloomberg videos, provided by MT Newswires